EDP-938
EDP 938-103
Phase 2 small_molecule terminated
Quick answer
EDP-938 for Respiratory Syncytial Virus Infections is a Phase 2 program (small_molecule) at ENANTA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ENANTA PHARMACEUTICALS INC
- Indication
- Respiratory Syncytial Virus Infections
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated